Lineage Cell Therapeutics, Inc.
LCTX· NYSE
LCTXLineage Cell Therapeutics, Inc.
Source filing unavailable
| Metric | Q4 2011 | Q4 2010dderived from reported figures |
|---|---|---|
| Revenue | $1.63M | — |
| Net Income | -$5.14M | — |
| EPS Diluted | -$0.10 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
